Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Research highlights potential of computers to enhance quality of care, medical outcomes

A computer system was more effective than doctors at collecting information about patient symptoms, producing reports that were more complete, organized and useful than narratives generated by physicians during office visits, according to a Cedars-Sinai study.

10 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

PRM-151 compound shows positive results for treating advanced myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

8 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Cepheid gets FDA clearance to market Xpert Norovirus

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market Xpert Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII).

1 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

Children with NAFLD at substantial risk for high blood pressure

High blood pressure and nonalcoholic fatty liver disease (NAFLD) are two emerging health problems related to the epidemic of childhood obesity. In a recent study, researchers at University of California, San Diego School of Medicine sought to determine the prevalence of high blood pressure in children with NAFLD, which places them at risk for premature cardiovascular disease.

24 Nov 2014

UC San Diego Health System opens nation's first angioedema treatment center

UC San Diego Health System in partnership with the U.S. Hereditary Angioedema Association, a non-profit patient advocacy organization, has opened the nation's first dedicated center for diagnosing and treating diverse forms of swelling, known collectively as angioedema.

24 Nov 2014

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

In a potential breakthrough against ovarian cancer, University of Guelph researchers have discovered how to both shrink tumours and improve drug delivery, allowing for lower doses of chemotherapy and reducing side effects.

13 Nov 2014

People with celiac disease have reactions to non-gluten wheat proteins

Although gluten-free foods are trendy among the health-conscious, they are necessary for those with celiac disease. But gluten, the primary trigger for health problems in these patients, may not be the only culprit. Scientists are reporting in ACS' Journal of Proteome Research that people with the disease also have reactions to non-gluten wheat proteins. The results could help scientists better understand how the disease works and could have implications for how to treat it.

6 Nov 2014

Abdominal Pain News and Research

Further Reading

Research highlights potential of computers to enhance quality of care, medical outcomes

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

PRM-151 compound shows positive results for treating advanced myelofibrosis

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Cepheid gets FDA clearance to market Xpert Norovirus

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Children with NAFLD at substantial risk for high blood pressure

UC San Diego Health System opens nation's first angioedema treatment center

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

People with celiac disease have reactions to non-gluten wheat proteins

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Astellas' isavuconazole gets FDA orphan drug designation for treatment of invasive candidiasis

Autism Speaks grants $1M to Children's Hospital Los Angeles to improve GI symptoms associated with ASD

Passengers from West Africa to start 3-week Ebola screening

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

UB study: Males with IBS experience more interpersonal difficulties than females

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News